Clostridium (e.g., Clostridium Tetani, Etc.) Patents (Class 424/239.1)
-
Publication number: 20090304747Abstract: This disclosure provides a method of treating urologic and related disorders, for example, urinary incontinence, in women through the administration of a composition comprising a neurotoxin and DMSO. Methods for making and using the described compositions are also provided.Type: ApplicationFiled: May 9, 2007Publication date: December 10, 2009Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventor: Steven P. Petrou
-
Patent number: 7628992Abstract: A chemical conjugate for treating a nerve cell related disorder is provided. This conjugate includes an active or inactive Clostridial toxin having specificity for a target nerve cell. The toxin is conjugated to a drug or other bioactive molecule without affecting the toxin's ability to enter the target nerve cell.Type: GrantFiled: September 28, 2000Date of Patent: December 8, 2009Assignee: Invent DCU LimitedInventors: James Oliver Dolly, Larry Allen Wheeler, Kei Roger Aoki, Michael Elwood Garst
-
Patent number: 7622127Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.Type: GrantFiled: June 20, 2007Date of Patent: November 24, 2009Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Publication number: 20090274729Abstract: Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing Clostridium botulinum bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.Type: ApplicationFiled: July 10, 2009Publication date: November 5, 2009Applicant: ALLERGAN, INC.Inventors: PING WANG, STEPHEN DONOVAN
-
Patent number: 7608275Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.Type: GrantFiled: July 21, 2006Date of Patent: October 27, 2009Assignee: The Foundry, LLCInventors: Mark E. Deem, Hanson Gifford
-
Publication number: 20090263426Abstract: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.Type: ApplicationFiled: October 23, 2008Publication date: October 22, 2009Applicant: ALLERGAN, INC.Inventors: CATHERINE C. TURKEL, MITCHELL F. BRIN
-
Publication number: 20090252764Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.Type: ApplicationFiled: April 3, 2008Publication date: October 8, 2009Inventor: Andrew M. Blumenfeld
-
Patent number: 7597891Abstract: A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided wherein dimeric or polymeric IgA is modified with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.Type: GrantFiled: August 16, 2007Date of Patent: October 6, 2009Inventor: Michael R. Simon
-
Publication number: 20090232851Abstract: The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous, separate or sequential therapeutic use in the treatment or prevention of pain and of neuromuscular disorders.Type: ApplicationFiled: June 11, 2007Publication date: September 17, 2009Inventors: Michel Auguet, Christine Favre, Pierre-Etienne Chabrier De Lassauniere
-
Publication number: 20090232850Abstract: Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.Type: ApplicationFiled: March 13, 2008Publication date: September 17, 2009Inventors: Aubrey N. Manack, Mitchell F. Brin
-
Publication number: 20090232849Abstract: Compositions and a method for sensitizing a cancer for treatment by cytotoxic therapy is disclosed. The method includes the step of administering to the cancerous tissue or cells a pharmaceutical composition containing a Botulinum toxin, BT.Type: ApplicationFiled: October 17, 2005Publication date: September 17, 2009Applicant: Universite Catholique de LouvainInventors: Bernard Gallez, Reginald Ansiaux
-
Publication number: 20090226468Abstract: The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and -gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells.Type: ApplicationFiled: June 21, 2007Publication date: September 10, 2009Applicant: Institut PasteurInventors: Laurent Coen, Rosario Osta Pinzolas, Philippe Brulet
-
Publication number: 20090220568Abstract: Methods of treating a urethral stricture in a patient. The methods can include the step of administering an therapeutically effective amount of a botulinum toxin directly to a urethra of the patient, for example by use of a stent from which the botulinum toxin can elute or diffuse, thereby treating the urethra stricture.Type: ApplicationFiled: May 6, 2009Publication date: September 3, 2009Applicant: ALLERGAN, INC.Inventors: Gregory F. BROOKS, Stephen DONOVAN
-
Publication number: 20090209937Abstract: Disclosed herein are apparatuses and methods for treating a neurological disorder associated with excessive neuronal excitability (e.g., epilepsy). Methods disclosed herein comprise administering to a subject in need of such treatment an antiepileptic drug solution comprising a therapeutically effective amount of an antiepileptic drug (e.g., a toxin that inhibits the exocytosis of neurotransmifters, excitotoxins, etc.) using convection-enhanced delivery (CED).Type: ApplicationFiled: August 8, 2008Publication date: August 20, 2009Applicant: ARGENIS LLCInventors: Michael Andrew ROGAWSKI, Maciej GASIOR
-
Publication number: 20090202591Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: ApplicationFiled: April 1, 2009Publication date: August 13, 2009Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20090186052Abstract: The invention concerns the use or a fragment of botulinum toxin having said toxin activity for preparing a medicine for reversibly desensitizing an area of the skin, said skin area being designed to receive injections. Said injections can be related, for example, to repeated delivery of insulin, growth hormones or other medicines in injectable form.Type: ApplicationFiled: December 21, 2005Publication date: July 23, 2009Applicant: Societe de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)Inventor: Roland Cherif-Cheikh
-
Patent number: 7560251Abstract: Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing Clostridium botulinum bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.Type: GrantFiled: December 12, 2006Date of Patent: July 14, 2009Assignee: Allgergan, Inc.Inventors: Ping Wang, Stephen Donovan
-
Patent number: 7556817Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region.Type: GrantFiled: September 19, 2006Date of Patent: July 7, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Melvin S. Oka
-
Publication number: 20090155348Abstract: The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as immunogens for the production of vaccines and antitoxins, as well as research and drug development applications. Clostridium botulinum is responsible for food bone botulism, a severe and often deadly disease. Botulinum neurotoxin binds to neural cells and are translocated into the cytosol. The toxin then prevents neurotransmitter release by cleaving a SNARE protein. A double mutant E224A/E262 full length botulinum neurotoxin Type A holo form was successfully cloned and purified, which lacks the endopeptidase activity involved in the toxic action of the BoNT, and thus leading to its detoxification (DR BoNT/A). This new molecule can be used as an antidote against botulism, and also as a vaccine candidate for botulism. Due to the poor availability and extreme toxicity of native holo-toxin, a nontoxic form of the holo-toxin is highly desired for research and vaccine development.Type: ApplicationFiled: September 19, 2008Publication date: June 18, 2009Inventors: Bal Ram Singh, Weiping Yang
-
Publication number: 20090155278Abstract: Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed in the majority of breast cancers, and claudins 3 and 4 are overexpressed. The methods of treatment involve the use of Clostridium perfringens enterotoxin (or a variant thereof) to lyse metastatic cancer cells in the brain and bone that overexpress claudins 3 and 4.Type: ApplicationFiled: March 7, 2008Publication date: June 18, 2009Inventors: Saraswati V. Sukumar, Scott L. Kominsky
-
Publication number: 20090155314Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.Type: ApplicationFiled: December 12, 2007Publication date: June 18, 2009Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
-
Publication number: 20090148476Abstract: Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less than dosages associated with treatment of regional movement diseases, since the agent works to reduce inflammation by reducing histamine and other preformed mediator releases associated with mast cell degranulation.Type: ApplicationFiled: December 31, 2008Publication date: June 11, 2009Inventor: Gary E. Borodic
-
Publication number: 20090142362Abstract: Improved vaccine compositions and methods of use thereof are described that elicit production of antibodies in an individual to the individual's own endogenous cholesteryl ester transfer protein (CETP).Type: ApplicationFiled: November 6, 2007Publication date: June 4, 2009Applicants: Avant Immunotherapeutics, Inc., Coley Pharmaceutical Group, Inc.Inventors: Arthur M. Krieg, Lawrence J. Thomas, Charles W. Rittershaus
-
Patent number: 7534863Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: GrantFiled: January 8, 2004Date of Patent: May 19, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Publication number: 20090123497Abstract: Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.Type: ApplicationFiled: October 31, 2007Publication date: May 14, 2009Applicant: ALLERGAN, INC.Inventors: Mingjiang Luo, Hui Xiang, Yao Yu, Stephen Donovan
-
Publication number: 20090123498Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.Type: ApplicationFiled: March 13, 2008Publication date: May 14, 2009Applicant: ALLERGAN, INCInventors: K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
-
Patent number: 7531179Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: March 29, 2007Date of Patent: May 12, 2009Assignee: Allergan, Inc.Inventor: M. Zouhair Atassi
-
Patent number: 7531183Abstract: An isolated, biologically active 33 kDa Hemagglutinin purified from the type A Clostridium botulinum neurotoxin complex and its uses are described.Type: GrantFiled: November 22, 2005Date of Patent: May 12, 2009Assignee: University of MassachusettsInventors: Bal Ram Singh, Shashi Kant Sharma
-
Publication number: 20090117157Abstract: The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such modified Clostridial toxins and compositions.Type: ApplicationFiled: October 21, 2008Publication date: May 7, 2009Inventors: Mitchell F. Brin, Joseph Francis, Kei Roger Aoki
-
Publication number: 20090104234Abstract: The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such modified Clostridial toxins and compositions.Type: ApplicationFiled: October 21, 2008Publication date: April 23, 2009Inventors: Joseph Francis, Kei Roger Aoki
-
Patent number: 7514088Abstract: The present invention is directed to multivalent Clostridial neurotoxin derivatives having more than one binding domain directed to a cell surface feature of a target cell. Such modified neurotoxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.Type: GrantFiled: March 15, 2006Date of Patent: April 7, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Fernandez-Salas Ester, Joseph Francis, Shengwin Li, Marcella A. Gilmore, Kei Roger Aoki
-
Publication number: 20090087458Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: ApplicationFiled: July 22, 2008Publication date: April 2, 2009Inventors: J. Oliver Dolly, Yan Li, Kuo Chion Chan
-
Publication number: 20090087459Abstract: The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and/or a Clostridial botulinum.Type: ApplicationFiled: November 14, 2008Publication date: April 2, 2009Applicant: ALLERGAN, INC.Inventor: Eric R. FIRST
-
Publication number: 20090087457Abstract: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.Type: ApplicationFiled: March 3, 2006Publication date: April 2, 2009Applicant: REVANCE THERAPEUTICS, INC.Inventors: Michael D. Dake, Jacob M. Waugh
-
Publication number: 20090068227Abstract: The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.Type: ApplicationFiled: November 11, 2008Publication date: March 12, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADOInventor: Richard A. Schmidt
-
Patent number: 7501130Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.Type: GrantFiled: April 13, 2006Date of Patent: March 10, 2009Assignee: Allergan, Inc.Inventors: K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
-
Publication number: 20090060953Abstract: Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided.Type: ApplicationFiled: October 16, 2008Publication date: March 5, 2009Inventor: Ira Sandars
-
Patent number: 7494661Abstract: Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided.Type: GrantFiled: June 28, 2001Date of Patent: February 24, 2009Inventor: Ira Sanders
-
Patent number: 7491403Abstract: Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target region of a particular tissue. The present invention provides compositions of botulinum toxin and a sequestration agent that increase sequestration and delivery of the botulinum toxin to neural and associated tissues, as compared with available formulations of botulinum toxins, and thereby produce a beneficial clinical effect. The sequestration agents of the present invention include proteins, lipids and carbohydrates. A preferred composition of the present invention comprises a botulinum toxin and an albumin. The present invention also provides methods of treating neuromuscular diseases and pain using the disclosed compositions and methods of making the disclosed compositions.Type: GrantFiled: December 22, 2003Date of Patent: February 17, 2009Assignee: Botulinum Toxin Research AssociatesInventor: Gary Borodic
-
Publication number: 20090041805Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.Type: ApplicationFiled: October 4, 2006Publication date: February 12, 2009Applicant: ALLERGAN, INC.Inventor: PATRICIA S. WALKER
-
Publication number: 20090041806Abstract: Methods of treating spasticity by administering a colonically absorbable prodrug of a GABA analog having antispastic activity that is not directly mediated by the GABAB receptor, optionally in combination with an antispasticity agent or a colonically absorbable prodrug of a GABAB receptor agonist are disclosed. In particular, methods of treating spasticity by administering a colonically absorbable prodrug of gabapentin or a colonically absorbable prodrug of pregabalin, in combination with a colonically absorbable prodrug of R-baclofen are disclosed.Type: ApplicationFiled: June 13, 2008Publication date: February 12, 2009Applicant: XenoPort, Inc.Inventor: Kenneth C. CUNDY
-
Publication number: 20090028906Abstract: The present invention relates to a method for providing a muscle relaxant at temperatures above 20° C., wherein said muscle relaxant is a solid dry composition comprising the neurotoxic component of botulinum toxin free of complexing proteins.Type: ApplicationFiled: May 29, 2008Publication date: January 29, 2009Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Swen Grein, Gerd J. Mander, Matthias Marx
-
Publication number: 20090028907Abstract: The invention relates to the use of a liquid or semi-solid formulation of botulinum toxin for the preparation of a medicament intended to treat a disorder characterised by bladder spasms (e.g. urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor sphincter, urinary retention secondary to spastic sphincter or hypertrophied bladder neck and neurogenic bladder dysfunction secondary to Parkinson's disease, spinal cord injury, stroke or multiple sclerosis or characterised by a spasm reflex), wherein said medicament is for administration by infusion into the bladder or by other methods that do not involve injection into the bladder wall.Type: ApplicationFiled: May 29, 2008Publication date: January 29, 2009Inventors: Chris Dott, John Batchelor, Pierre Bernard D'Arbigny, Roland Cherif-Cheikh
-
Publication number: 20090028908Abstract: The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain.Type: ApplicationFiled: August 6, 2008Publication date: January 29, 2009Inventor: Stephen Donovan
-
Publication number: 20090022763Abstract: Media and processes for the fermentation of Clostridium botulinum and obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially free of animal derived products.Type: ApplicationFiled: September 19, 2008Publication date: January 22, 2009Applicant: ALLERGAN, INC.Inventor: Stephen DONOVAN
-
Patent number: 7479281Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.Type: GrantFiled: October 4, 2006Date of Patent: January 20, 2009Assignee: Allergan, Inc.Inventor: Patricia S. Walker
-
Publication number: 20090016988Abstract: The present invention provides modified pore-forming protein toxins (MPPTs), capable of being used to kill cancer cells. The MPPTs according to the present invention comprise a modification of the naturally occurring activation sequence comprising one or more general cleavage sites, each of which is cleavable by general activating agent, or a plurality of specific cleavage sites, each of which is cleavable by a specific activating agent. Optional further modifications that allow specific targeting of these molecules are also described. These MPPTs may be used to treat cancer.Type: ApplicationFiled: November 21, 2006Publication date: January 15, 2009Inventor: J. Thomas Buckley
-
Publication number: 20090017071Abstract: The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amount of a composition which includes a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain.Type: ApplicationFiled: August 6, 2008Publication date: January 15, 2009Inventor: Stephen Donovan
-
Publication number: 20090010944Abstract: The invention relates to methods of producing, and compositions comprising, an isolated alpha (2?8) or (2?9) oligosialic acid derivative bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exoneuraminidase. A representative production method involves: (i) treating an alpha (2?8) or (2?9) oligosialic acid precursor having a reducing end and a non-reducing end with sodium borohydride under conditions for de-N-acetylating the non-reducing end; and (ii) isolating alpha (2?8) or (2?9) oligosialic acid derivative having one or more de-N-acetylated residues and a non-reducing end that is resistant to degradation by exoneuraminidase. Isolated alpha (2?8) or (2?9) oligosialic acid derivatives that comprise a non-reducing end de-N-acetyl residue are provided, as well as antibodies specific for the derivatives, compositions comprising the derivatives, kits, and methods of use including protection against and detection of E. coli K1 and N.Type: ApplicationFiled: July 3, 2008Publication date: January 8, 2009Inventors: Gregory R. Moe, Brent T. Hagen
-
Publication number: 20090010967Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.Type: ApplicationFiled: October 26, 2007Publication date: January 8, 2009Inventor: STEPHEN DONOVAN